Phaseline

Targets › OPRT

OPRT: drug programs, companies and trials

1 program from 1 company in 4 trials: 3 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on OPRT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cancer Institute and Hospital, Chinese Academy of Medical SciencesS-1
Fluorouracil prodrug; inhibits thymidylate synthase and orotate phosphoribosyltransferase
TYMS, OPRTPhase 2Biliary Tract Cancer; Pancreatic Adenocarcinoma; Intrahepatic Cholangiocarcinoma (Icc); Neuroendocrine TumorsDec 2026

Conditions

Biliary Tract Cancer (1) Pancreatic Adenocarcinoma (1) Intrahepatic Cholangiocarcinoma (Icc) (1) Neuroendocrine Tumors (1)

Modalities

–

Companies

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Related targets

TYMS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.